Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.
about
Animal models of hemophiliaDifferential proteolytic activation of factor VIII-von Willebrand factor complex by thrombinLessons Learned from Animal Models of Inherited Bleeding Disorders.A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophiliaThe Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion.Purification and characterization of a new recombinant factor VIII (N8).Clinical application of a rapid method using agarose gel electrophoresis and Western blotting to evaluate von Willebrand factor protease activity.Long-term expression of canine FVIIa in hemophilic dogsEffect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand diseaseRecombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimerasA monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice.Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B.In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies.Correction of a murine model of von Willebrand disease by gene transfer.Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality.Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells.Effect of synthetic colloid administration on coagulation in healthy dogs and dogs with systemic inflammationIn vivo models of haemophilia - status on current knowledge of clinical phenotypes and therapeutic interventions.Animal models of hemophilia and related bleeding disorders.Successful treatment of canine hemophilia by continuous expression of canine FVIIa.Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs.Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review.Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments.The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor.The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII.Characterization of des-(741-1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa.Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIIIEvaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys713-Arg740: discordant in vitro and in vivo activity.Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins.Models for assessing immunogenicity and efficacy of new therapeutics for the treatment of haemophilia.Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophilia A carriers: consequences for therapy and genetic counselling.von Willebrand factor plasma levels, genetic variations and coronary heart disease in an older population.
P2860
Q27012571-997F70CA-97E1-4668-98CF-93DCBC6EEE80Q28630604-330F5D34-0E08-442E-9BF6-B8786204DE7DQ30409863-988197AF-4246-41C1-BCAA-B68D9DDD6EE7Q30442996-B3716809-5E9D-4727-83F0-3F55CF9AB22BQ30443003-ADF83BE7-EE37-48F5-85B5-867F330D8A21Q30745198-DBFB7B8B-0600-44F4-8B57-672BE586A81DQ30881997-CE78C5EF-7E24-4227-9CE2-06D0B0E198C2Q33337162-88D90368-88BA-42CB-A61E-7B20AFD21D3DQ33802667-D6FBEB9E-8E0F-4810-A1BE-13C55536C7CAQ33838757-1A1019DA-5536-4B6E-B5B3-D359FF6E6B88Q34078730-F31DD982-D7FF-4E0F-BAD4-4404E3F8F314Q34468951-2F4F1897-4C23-43B8-A0D6-D700F651BE18Q34576333-02995306-7AB9-4C12-BDDB-097DFCA1470FQ34675871-6F37026C-C716-4968-87BE-DE5E25C3B20CQ35006603-6B731A28-3FC1-4092-8313-EAF6AAD5389AQ35006608-08AD68A8-195E-4518-96C1-DDE289159210Q35109095-CF17176F-BD38-47F0-B251-C1793668B0FEQ35536246-05FD960A-1774-4711-B265-6CBA8FAA32AEQ35849850-730AD660-B403-4A3B-AFBD-0389BA000275Q36532500-86AAA9DD-ED82-4EA6-8B98-45EC771DCAD7Q36768042-766A65F6-1324-4110-96CC-DD4E921ED9CCQ36873688-CD3333DE-AA48-4C8B-94D6-27A8BCC4A112Q37056724-355F3929-DD6C-446D-B42B-BA6BB0EEE0A9Q37091290-A05383EE-1F9D-4574-B049-89411E66F8D2Q37162830-9DF27EF8-D705-4413-82F8-7ACAC05D9C32Q37316242-1C709593-20C9-4B32-818B-CB9C2C5E2B51Q37585275-4F35E661-D567-4C25-90C0-1CD6CBA55159Q37845944-6412D884-815A-4A84-8BE3-94EF9279FB32Q40959030-47BA68C1-FF1F-4AF6-9DF7-F94F479C3620Q41258205-A3698A30-79DA-495C-B71E-74E65C999A02Q41695401-5602FC0C-954E-45DF-B5FB-FDD7AB29275CQ41778291-5765C2DA-FDF1-4515-A5D1-D97D0317A833Q41828726-B15B5245-03DE-49A2-B9CA-274DFBA29835Q42532943-189A408D-6741-4502-82D7-4BE73537B9C5Q45856650-1CBB8BED-63CA-48A1-9DDD-3A2B1250DE2AQ45873498-72053784-370E-48C6-9F97-4A11E0A10A69Q45878358-0AE91468-F8D3-47FD-8A72-0D98D7AC455CQ45879922-595342BC-5570-45EF-8CE2-0D1B97AE9AFDQ45882688-EF5A30CA-93E1-4CB9-8832-04881694F68FQ47793649-3D82585B-4D48-4220-895B-626834913FAD
P2860
Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 1985
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Purified human factor VIII pro ...... d von Willebrand disease dogs.
@en
Purified human factor VIII pro ...... d von Willebrand disease dogs.
@nl
type
label
Purified human factor VIII pro ...... d von Willebrand disease dogs.
@en
Purified human factor VIII pro ...... d von Willebrand disease dogs.
@nl
prefLabel
Purified human factor VIII pro ...... d von Willebrand disease dogs.
@en
Purified human factor VIII pro ...... d von Willebrand disease dogs.
@nl
P2093
P2860
P356
P1476
Purified human factor VIII pro ...... d von Willebrand disease dogs.
@en
P2093
C Mattsson
H Sandberg
J B Garris
K M Brinkhous
P2860
P304
P356
10.1073/PNAS.82.24.8752
P407
P577
1985-12-01T00:00:00Z